Globe Newswire04.07.20
Endonovo Therapeutics Inc. is collaborating with a Stanford University-sponsored Orthopedic Shoulder and Knee Study to determine benefits of Endonovo's tPEMF SofPulse on pain, medication levels and physical function post-operatively.
The Stanford University study official title is “A Pilot Prospective, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Pulsed Electromagnetic Field (PEMF) Therapy in Decreasing Post-Operative Pain Following Orthopedic Surgery.” The orthopedic-focused study will evaluate 76 patients with Active and Sham Comparator groups, measured by visual analog scale (VAS), at 10 days after and will allow surgeons to determine the efficacy of Endonovo's SofPulse tPEMF portable device postoperatively. Board certified orthopedic surgeon Dr. Geoffrey D. Abrams is the key investigator and will be conducting the study.
Endonovo's SofPulse tPEMF portable device—cleared by the U.S. Food and Drug Administration—is a non-invasive, drug-free non-opioid treatment for postoperative pain and edema presently being adopted for use in major hospitals and clinics nationwide. Endonovo Therapeutics collaboration and participation on multiple efficacy studies, clinical evaluations and adaption by nationwide hospitals will further show the efficacy and effectiveness on PEMF SofPulse treatments and therapy.
Endonovo Chief Medical Officer Dr. Nev Zubcevik D.O., “The study will allow surgeons to determine if PEMF SofPulse therapy is beneficial in reducing patient-reported post-operative pain. Surgeons will be able to make observations on the amount of pain medication taken daily and the physical function outcome scores after surgery and PEMF treatment.”. Results of the study will be published as detailed here.
Dr. Zubcevik continued, “Past published clinical efficacy studies for tPEMF SofPulse have shown 2.2X reduction of post-op use of narcotics at 48 hours, 300 percent reduction of pain scores which relates to nearly a three times faster reduction in the need for pain medication post-op and 275 percent reduction in inflammation and swelling at 18 hours postoperatively.”
The Stanford University study official title is “A Pilot Prospective, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Pulsed Electromagnetic Field (PEMF) Therapy in Decreasing Post-Operative Pain Following Orthopedic Surgery.” The orthopedic-focused study will evaluate 76 patients with Active and Sham Comparator groups, measured by visual analog scale (VAS), at 10 days after and will allow surgeons to determine the efficacy of Endonovo's SofPulse tPEMF portable device postoperatively. Board certified orthopedic surgeon Dr. Geoffrey D. Abrams is the key investigator and will be conducting the study.
Endonovo's SofPulse tPEMF portable device—cleared by the U.S. Food and Drug Administration—is a non-invasive, drug-free non-opioid treatment for postoperative pain and edema presently being adopted for use in major hospitals and clinics nationwide. Endonovo Therapeutics collaboration and participation on multiple efficacy studies, clinical evaluations and adaption by nationwide hospitals will further show the efficacy and effectiveness on PEMF SofPulse treatments and therapy.
Endonovo Chief Medical Officer Dr. Nev Zubcevik D.O., “The study will allow surgeons to determine if PEMF SofPulse therapy is beneficial in reducing patient-reported post-operative pain. Surgeons will be able to make observations on the amount of pain medication taken daily and the physical function outcome scores after surgery and PEMF treatment.”. Results of the study will be published as detailed here.
Dr. Zubcevik continued, “Past published clinical efficacy studies for tPEMF SofPulse have shown 2.2X reduction of post-op use of narcotics at 48 hours, 300 percent reduction of pain scores which relates to nearly a three times faster reduction in the need for pain medication post-op and 275 percent reduction in inflammation and swelling at 18 hours postoperatively.”